N6-benzoil-2′-deoxi-5′-O-(4,4′-dimetoxitritil)adenosina 3′-(2-cianoetil diisopropilfosforamidita)

non-animal source (no BSE/TSE risk)

300

for DNA synthesis

Proligo Reagents

≥99.5% (reversed phase HPLC), >99.5% (³¹P-NMR)

powder or granules

oligo synthesis: suitable

>= 170ppm, none detected (S/N <2.5), ≤0.1% single unspecified Imprity (reversed phase HPLC), ≤0.3% P(III) 100-169ppm (³¹P-NMR), ≤0.3% dA2 (reversed phase HPLC, DMT-dA(bz) cyanoethyl-H-posphonate), ≤0.3% dA3 (reversed phase HPLC, DMT-dA(bz) phosphoramidate), ≤0.30 wt. % water content (Karl Fischer), ≤0.5% P(V) -25-99ppm (³¹P-NMR), ≤3.0 wt. % residual solvent content

white to off-white

soluble, clear

conforms to structure for H-NMR, conforms to structure for LC-MS

base: deoxyadenosine
base protecting group: benzoyl
2' protecting group: none
5' protecting group: DMT
deprotection: standard

2-8°C

COc1ccc(cc1)C(OC[C@H]2O[C@H](C[C@@H]2OP(OCCC#N)N(C(C)C)C(C)C)n3cnc4c(NC(=O)c5ccccc5)ncnc34)(c6ccccc6)c7ccc(OC)cc7

1S/C47H52N7O7P/c1-32(2)54(33(3)4)62(59-27-13-26-48)61-40-28-42(53-31-51-43-44(49-30-50-45(43)53)52-46(55)34-14-9-7-10-15-34)60-41(40)29-58-47(35-16-11-8-12-17-35,36-18-22-38(56-5)23-19-36)37-20-24-39(57-6)25-21-37/h7-12,14-25,30-33,40-42H,13,27-29H2,1-6H3,(H,49,50,52,55)/t40-,41+,42+,62?/m0/s1

GGDNKEQZFSTIMJ-AKWFTNRHSA-N